Anti-VEGF treatment strategies for wet AMD

Journal of Ophthalmology

Volumn 2012, Issue , 2012, Pages

  Kovach, Jaclyn L ^a   Schwartz, Stephen G ^a   Flynn, Harry W ^a   Scott, Ingrid U ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869225440     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2012/786870     Document Type: Review

References (45)

1. Nowak J. Z., Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacological Reports 2006 58 3 353 363 2-s2.0-33746373850 (Pubitemid 44111070)
2. Ferrara N., Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 2004 25 4 581 611 2-s2.0-4143136640 10.1210/er.2003-0027 (Pubitemid 39099316)
3. Bressler S. B., Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration. Ophthalmology 2009 116 10 S1 S7 2-s2.0-70349449737 10.1016/j.ophtha.2009.06.045
4. Krzystolik M. G., Afshari M. A., Adamis A. P., Gaudreault J., Gragoudas E. S., Michaud N. A., Li W., Connolly E., O'Neill C. A., Miller J. W., Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Archives of Ophthalmology 2002 120 3 338 346 2-s2.0-0036129304 (Pubitemid 34250056)
5. Husain D., Kim I., Gauthier D., Lane A. M., Tsilimbaris M. K., Ezra E., Connolly E. J., Michaud N., Gragoudas E. S., O'Neill C. A., Beyer J. C., Miller J. W., Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Archives of Ophthalmology 2005 123 4 509 516 2-s2.0-20144387561 10.1001/archopht.123.4.509 (Pubitemid 40489924)
6. Gragoudas E. S., Adamis A. P., Cunningham E. T., Feinsod M., Guyer D. R., Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 2004 351 27 2805 2816 2-s2.0-11144239923 10.1056/NEJMoa042760 (Pubitemid 40051904)
7. VISION Clinical Trial Group, Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006 113 1508 1521
8. Steinbrook R., rsteinbrook@attglobal.net The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. New England Journal of Medicine 2006 355 14 1409 1412 10.1056/NEJMp068185 (Pubitemid 44511554)
9. Sharma S., Kaiser P. K., Update on VEGF Trap-Eye clinical trials. Retinal Physician November 2010
10. Ferrara N., Hillan K. J., Gerber H. P., Novotny W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews Drug Discovery 2004 3 5 391 400 2-s2.0-2442621619 (Pubitemid 38618122)
11. Tolentino M. J., Husain D., Theodosiadis P., Gragoudas E. S., Connolly E., Kahn J., Cleland J., Adamis A. P., Cuthbertson A., Miller J. W., jwmiller@meei.harvard.edu Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Archives of Ophthalmology 2000 118 1 78 84 (Pubitemid 30036442)
12. Moshfeghi A. A., Rosenfeld P. J., Puliafito C. A., Michels S., Marcus E. N., Lenchus J. D., Venkatraman A. S., Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006 113 11 2002 2011 2-s2.0-33750305221 10.1016/j.ophtha.2006.05.070 (Pubitemid 44642322)
13. Rosenfeld P. J., Moshfeghi A. A., Puliafito C. A., Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery Lasers and Imaging 2005 36 4 331 335 2-s2.0-23044505200 (Pubitemid 41073112)
14. Avery R. L., Pieramici D. J., Rabena M. D., Castellarin A. A., Nasir M. A., Giust M. J., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 114 2 363 400 2-s2.0-33644502828 10.1016/j.ophtha.2005.11.019
15. Ferrara N., Damico L., Shams N., Lowman H., Kim R., Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006 26 8 859 870 2-s2.0-33749632278 10.1097/01.iae.0000242842.14624.e7 (Pubitemid 44547437)
16. Stewart M. W., Predicted biologic activity of intravitreal bevacizumab. Retina 2007 27 9 1196 1200 2-s2.0-36749023451 10.1097/IAE.0b013e318158ea28 (Pubitemid 350211524)
17. Bakri S. J., Snyder M. R., Reid J. M., Pulido J. S., Ezzat M. K., Singh R. J., Pharmacokinetics of intravitreal ranibizumab. Ophthalmology 2007 114 12 2179 2182 2-s2.0-36549039554 10.1016/j.ophtha.2007.09.012 (Pubitemid 350181137)
18. Pegaptanib Product Information
19. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V., Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Investigative Ophthalmology and Visual Science 2005 46 2 726 733 2-s2.0-13944266313 10.1167/iovs.04-0601 (Pubitemid 40270359)
20. Rosenfeld P. J., prosenfeld@med.miami.edu Brown D. M., Heier J. S., Boyer D. S., Kaiser P. K., Chung C. Y., Kim R. Y., Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006 355 14 1419 1431 10.1056/NEJMoa054481 (Pubitemid 44511557)
21. Brown D. M., Kaiser P. K., Michels M., Soubrane G., Heier J. S., Kim R. Y., Sy J. P., Schneider S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 2006 355 14 1432 1444 2-s2.0-33749451356 10.1056/NEJMoa062655 (Pubitemid 44511558)
22. Abraham P., Yue H., Wilson L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. American Journal of Ophthalmology 2010 150 3 315 324 2-s2.0-77956056292 10.1016/j.ajo.2010.04.011
23. Schmidt-Erfurth U., Eldem B., Guymer R., Korobelnik J. F., Schlingemann R. O., Axer-Siegel R., Wiedemann P., Simader C., Gekkieva M., Weichselberger A., Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration. the EXCITE study. Ophthalmology 2010 118 831 839 2-s2.0-78649768810 10.1016/j.ophtha.2010.09.004
24. Lalwani G. A., Rosenfeld P. J., Fung A. E., Dubovy S. R., Michels S., Feuer W., Davis J. L., Flynn H. W., Esquiabro M., A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. American Journal of Ophthalmology 2009 148 1 1 3 2-s2.0-67149101784 10.1016/j.ajo.2009.01.024
25. Boyer D. S., Heier J. S., Brown D. M., Francom S. F., Ianchulev T., Rubio R. G., A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 9 1731 1739 2-s2.0-69249222585 10.1016/j.ophtha.2009.05.024
26. Mitchell P., Korobelnik J. F., Lanzetta P., Holz F. G., Prünte C., Schmidt-Erfurth U., Tano Y., Wolf S., Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. British Journal of Ophthalmology 2010 94 1 2 13 2-s2.0-74549137478 10.1136/bjo.2009.159160
27. Ranibizumab safe and effective over long term in HORIZON extension study. Ophthalmology Times 2009
28. Engelbert M., Zweifel S. A., Freund K. B., «treat and extend» dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009 29 10 1424 1431 2-s2.0-73349096955 10.1097/IAE.0b013e3181bfbd46
29. Oubraham H., Cohen S. Y., Samimi S., Marotte D., Bouzaher I., Bonicel P., Fajnkuchen F., Tadayoni R., Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina 2010 31 1 26 30 2-s2.0-77957192554 10.1097/IAE. 0b013e3181de5609
30. Gupta O. P., Shienbaum G., Patel A. H., Fecarotta C., Kaiser R. S., Regillo C. D., A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology 2010 117 11 2134 2140 2-s2.0-78049279239 10.1016/j.ophtha.2010.02.032
31. Tufail A., Patel P. J., Egan C., Hykin P., Da Cruz L., Gregor Z., Dowler J., Majid M. A., Bailey C., Mohamed Q., Johnston R., Bunce C., Xing W., Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. British Medical Journal 2010 340 7761 1398 2-s2.0-77954106891 10.1136/bmj.c2459 c2459
32. Fong K. C. S., Kirkpatrick N., Mohamed Q., Johnston R. L., Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clinical and Experimental Ophthalmology 2008 36 8 748 755 2-s2.0-58149347420 10.1111/j.1442-9071.2008.01873.x
33. Mekjavic P. J., Kraut A., Urbancic M., Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmologica 2009 89 7 647 653
34. Leydolt C., Michels S., Prager F., Garhoefer G., Georgopoulos M., Polak K., Schmidt-Erfurth U., Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmologica 2010 88 5 594 600 2-s2.0-77954645507 10.1111/j.1755-3768.2008.01485.x
35. Luu S. T., susie.luu@health.sa.gov.au Gray T., Warrier S. K., Patel I., Muecke J. S., Casson R., Gilhotra J. S., Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clinical and Experimental Ophthalmology 2010 38 7 659 663 10.1111/j.1442-9071.2010.02309.x
36. Arevalo J. F., Snchez J. G., Wu L., Berrocal M. H., Alezzandrini A. A., Restrepo N., Maia M., Farah M. E., Brito M., Daz-Llopis M., Rodrguez F. J., Reategui G., Iturralde-Iraola J., Udaondo-Mirete P., Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the pan-american collaborative retina study. Ophthalmology 2010 117 10 1974 1981 2-s2.0-77957578064 10.1016/j.ophtha.2010.01. 056
37. Bashshur Z. F., Haddad Z. A., Schakal A. R., Jaafar R. F., Saad A., Noureddin B. N., Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. American Journal of Ophthalmology 2009 148 1 59 65 2-s2.0-67149131231 10.1016/j.ajo.2009.02.006
38. Treat-and-extend therapy a popular, cost-effective approach to treating neovascular AMD. PCONSuperSite 2011
39. Martin D. F., Maguire M. G., maguirem@mail.med.upenn.edu Ying G. -S., Grunwald J. E., Fine S. L., Jaffe G. J., Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2011 364 20 1897 1908 10.1056/NEJMoa1102673
40. Rosenfeld P. J., Bevacizumab versus ranibizumab-the verdict. New England Journal of Medicine 2011 364 20 1966 1967 10.1056/NEJMe1103334
41. Slakter J. S., What to do when anti-VEGF therapy fails. Retinal Physician 2010
42. Lee A. Y., Raya A. K., Kymes S. M., Shiels A., Brantley M. A., Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. British Journal of Ophthalmology 2009 93 5 610 613 2-s2.0-66149089631 10.1136/bjo.2008.150995
43. Brantley M. A., Fang A. M., King J. M., Tewari A., Kymes S. M., Shiels A., Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007 114 12 2168 2173 2-s2.0-36549016602 10.1016/j.ophtha.2007.09. 008 (Pubitemid 350181136)
44. Nguyen Q. D., Heier J., Brown D., Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF-Trap-Eye in wet AMD: one-year results of the VIEW-1 study. Proceedings of the Association for Research in Vision and Ophthalmology 2011 Fort Lauderdale, Fla, USA 3073
45. Schmidt-Erfurth U., Chong V., Kirchhof B., Primary results of an international phase III study using intravitreal VEGF Trap-Eye compared to ranibizumab in patients with wet AMD (VIEW 2). Proceedings of the Association for Research in Vision and Ophthalmology 2011 Fort Lauderdale, Fla, USA 1650